Masuoka, Shotaro
Nishio, Junko
Yamada, Soichi
Saito, Kosuke
Kaneko, Kaichi
Kaburaki, Makoto
Tanaka, Nahoko
Sato, Hiroshi
Muraoka, Sei
Kawazoe, Mai
Mizutani, Satoshi
Furukawa, Karin
Ishii-Watabe, Akiko
Kawai, Shinichi
Saito, Yoshiro
Nanki, Toshihiro
Funding for this research was provided by:
Toho University School of Medicine (20-01, 17-01)
Ministry of Education, Culture, Sports, Science and Technology (S1411015)
Article History
Received: 8 September 2023
Revised: 8 January 2024
Accepted: 7 February 2024
First Online: 24 February 2024
Declarations
:
: The study protocol was approved by the Ethics Committees of the Faculty of Medicine, Toho University (approval numbers: A22060_A19020_A17059_A16030 and A21014_A18084_27060) and National Institute of Health Sciences (approval numbers: 271, 271–2, 271–3). All participants provided their written informed consent for this study.
: JN received research funding from Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim Co., Ltd., Nippon Kayaku Co., Ltd., Ayumi Pharmaceutical Corp., Abbvie GK, Abbott Japan LLC, and GlaxoSmithKline plc. KK has received research grants and/or speaking fees from AbbVie GK, Astellas Pharma Inc., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline plc., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Teijin Pharma Ltd. HS has received speaking fees and/or teaching fees from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corp., and Taisho Pharmaceutical Co., Ltd. SMuraoka has received consultant fee from Asahi Kasei Pharma Corp., and speaker’s bureau from Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Asahi Kasei Pharma Corp. and Astellas Pharma Inc. MK has received speaking fees from Ayumi Pharmaceutical Corp., Asahi Kasei Pharma Corp., AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Gilead Sciences Inc, GlaxoSmithKline K.K., Mitsubishi-Tanabe Pharma Corp., Nippon Boehringer Ingelheim Co., Ltd. and Taisho Pharmaceutical Co., Ltd. SMizutani received lectures fees from Janssen Pharmaceutical K.K., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Mitsubishi-Tanabe Pharma Corp., Novartis Pharma K.K., Eli Lilly Japan K.K., Asahikasei Pharma Corp., Taisho Pharma Co., Ltd., and Ono Pharmaceutical Co., and speakers fees from Chugai Pharmaceutical Co., Ltd., Mitsubishi-Tanabe Pharma Corp., Novartis Pharma K.K., Asahikasei Pharma Corp. and Taisho Pharma Co., Ltd. SK has received research grants and/or speaking fees from AbbVie GK, Astellas Pharma Inc., Ayumi Pharmaceutical Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co. Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., Nippon Zoki Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. TN received grant/research support from Chugai Pharmaceutical Co., Ltd, Eisai Co., Ltd., Eli Lilly Japan K.K., Bristol Myers Squibb Co., Ono Pharmaceutical Co., Ltd., Asahikasei Pharma Corp., Mitsubishi Tanabe Pharma Corp., Ayumi Pharmaceutical Corp, Nippon Kayaku Co., Ltd., AbbVie GK, Sanofi K.K., Teijin Pharma Ltd., Taisho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., UCB Japan Co., Ltd., Pfizer Japan Inc. and Takeda Pharmaceutical Co., Ltd., consultant fees from UCB Japan Co., Ltd., Eisai Co., Ltd. and Chugai Pharmaceutical Co., Ltd., and speakers fees from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Astellas Pharma Inc., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Asahikasei Pharma Corp., Eli Lilly Japan K.K., Mylan N.V., AbbVie GK, Takeda Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corp., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., UCB Japan Co. Ltd., Nippon Kayaku Co., Ltd., Sanofi K.K., Teijin Pharma Ltd., Gilead Sciences, Inc. and Taisho Pharmaceutical Co., Ltd. The remaining authors declare that they have no conflicts of interest.